| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Radiology, Eugene L. Saenger Radioisotope Laboratory and the Division of Medical Physics, Department of Environmental Health, Division of Epidemiology and Biostatistics, University of Cincinnati Medical Center, Cincinnati, Ohio
Correspondence: For reprints contact: Harry R. Maxon III, MD, Director, Eugene L Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, 234 Goodman St., Cincinnati, OH 45267-0577.
ABSTRACT
For almost five decades, 131I treatment of thyroid cancer has been based empirically on administered activity rather than on actual radiation doses delivered. In 1983, we defined radiation dose thresholds for successful treatment. This report is concerned with the subsequent validation of those thresholds in 85 patients. The successful ablation of thyroid remnants occurred after a single initial 131I administration in 84% of inpatients and in 79% of outpatients when treatment was standardized to a radiation dose of at least 30,000 cGy (rad). Administered activities low enough to permit outpatient therapy could be used in 47% of the patients. Lymph node metastases were treated successfully in 74% of patients with a single administration of 131I calculated to deliver at least 8,500 cGy (rad). For athyrotic patients with nodal metastases only, success was achieved in 86% of patients at tumor doses of at least 14,000 cGy (rad). These success rates are equal to or better than those reported with empiric methods of 131I administration. The individualized treatment planning selectively allocates hospitalization and higher exposures to 131I to those patients who require them.
This article has been cited by other articles:
|
|
 |
|
  R. B T Verkooijen, F. A Verburg, J. W van Isselt, C. J M Lips, J. W Smit, and M. P M Stokkel The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies Eur. J. Endocrinol., September 1, 2008; 159(3): 301 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Silberstein Comparison of Outcomes After 123I Versus 131I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma J. Nucl. Med., July 1, 2007; 48(7): 1043 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A.R. Doi, N. J. Woodhouse, L. Thalib, and A. Onitilo Ablation of the Thyroid Remnant and I-131 Dose in Differentiated Thyroid Cancer: A Meta-Analysis Revisited Clin. Med. Res., June 1, 2007; 5(2): 87 - 90. [Full Text] [PDF]
|
|
|
|
|
|
R. B T Verkooijen, D. Rietbergen, J. W Smit, J. A Romijn, and M. P M Stokkel A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up Eur. J. Endocrinol., January 1, 2007; 156(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hackshaw, C. Harmer, U. Mallick, M. Haq, and J. A. Franklyn 131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 28 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y Liu, M. P Stokkel, A. M Pereira, E. P Corssmit, H. A Morreau, J. A Romijn, and J. W A Smit Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur. J. Endocrinol., April 1, 2006; 154(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Luster, F. Lippi, B. Jarzab, P. Perros, M. Lassmann, C. Reiners, and F. Pacini rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr. Relat. Cancer, March 1, 2005; 12(1): 49 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Bal, A. Kumar, and G. S. Pant Radioiodine Dose for Remnant Ablation in Differentiated Thyroid Carcinoma: A Randomized Clinical Trial in 509 Patients J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1666 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners Impact of 131I Diagnostic Activities on the Biokinetics of Thyroid Remnants J. Nucl. Med., April 1, 2004; 45(4): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sisson, B. L. Shulkin, and S. Lawson Increasing Efficacy and Safety of Treatments of Patients with Well-Differentiated Thyroid Carcinoma by Measuring Body Retentions of 131I J. Nucl. Med., June 1, 2003; 44(6): 898 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Robbins, S. M. Larson, N. Sinha, A. Shaha, C. Divgi, K. S. Pentlow, R. Ghossein, and R. M. Tuttle A Retrospective Review of the Effectiveness of Recombinant Human TSH as a Preparation for Radioiodine Thyroid Remnant Ablation J. Nucl. Med., November 1, 2002; 43(11): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pacini, E. Molinaro, M. G. Castagna, F. Lippi, C. Ceccarelli, L. Agate, R. Elisei, and A. Pinchera Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4063 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Lewis, I. D. Hay, J. W. Charboneau, B. McIver, C. C. Reading, and J. R. Goellner Percutaneous Ethanol Injection for Treatment of Cervical Lymph Node Metastases in Patients with Papillary Thyroid Carcinoma Am. J. Roentgenol., March 1, 2002; 178(3): 699 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S E M Clarke Advances in radionuclide imaging: radionuclide imaging as a guide to therapy Imaging, September 1, 2001; 13(3): 171 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F. Morris, A. D. Waxman, and G. D. Braunstein The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in 131I-Scanned and Nonscanned Individuals J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3507 - 3511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hermanska, M. Karny, J. Zimak, L. Jirsa, M. Samal, and P. Vlcek Improved Prediction of Therapeutic Absorbed Doses of Radioiodine in the Treatment of Thyroid Carcinoma J. Nucl. Med., July 1, 2001; 42(7): 1084 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]
|
|
|
|
|
|
P. Rotman-Pikielny, J. C. Reynolds, W. C. Barker, P. M. Yen, M. C. Skarulis, and N. J. Sarlis Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 237 - 244. [Abstract] [Full Text]
|
|
|
|
|
|
S.-S. Koong, J. C. Reynolds, E. G. Movius, A. M. Keenan, K. B. Ain, M. C. Lakshmanan, and J. Robbins Lithium as a Potential Adjuvant to 131I Therapy of Metastatic, Well Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 912 - 916. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Travagli, A. F. Cailleux, M. Ricard, E. Baudin, B. Caillou, C. Parmentier, and M. Schlumberger Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2675 - 2680. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. R. Kelemen, A. J. Van Herle, and A. E. Giuliano Sentinel Lymphadenectomy in Thyroid Malignant Neoplasms Arch Surg, March 1, 1998; 133(3): 288 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Schlumberger Papillary and Follicular Thyroid Carcinoma N. Engl. J. Med., January 29, 1998; 338(5): 297 - 306. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Emerson and R. Colzani Epithelial Cell Thyroid Cancer and Thyroid Stimulating Hormone--When Less is More J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 9 - 10. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
